secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001628280-26-011971
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics reports Q4 net loss $20.5M, cash $297M; cemsidomide Phase 2 trial dosed
--------------------------------------------------------------------------------

- Q4 revenue $11.0M, net loss $20.5M ($0.18/sh); full-year net loss $105.0M ($1.27/sh).
- Cash, equivalents and marketable securities $297.1M as of Dec 31, 2025; runway to end of 2028.
- First patient dosed in Phase 2 MOMENTUM trial of cemsidomide for multiple myeloma; designed for accelerated approval.
- Phase 1b trial of cemsidomide + elranatamab (Pfizer supply) to initiate Q2 2026; collaboration agreement signed Oct 2025.
- October 2025 raised $125M gross proceeds from underwritten offering; warrants could add $225M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828026011971/0001628280-26-011971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828026011971/cccc-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-011971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer